MedTrace Logo

Feasibility and Metabolic Effects of a 5:2 Fasting Intervention in Women With Breast Cancer During Radiotherapy

NCT05861362 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-05-16

No results posted yet for this study

Summary

The intervention consists of the adoption of a 5:2 intermittent fasting diet during radiotherapy of breast cancer patients. The aim of the study was to assess the feasibility of this intervention and its impact on body composition and selected metabolic blood parameters.

Conditions

Interventions

RADIATION

Curative radiotherapy

Curative radiotherapy as indicated by the patient's disease and prescribed by the treating radiation oncologist

BEHAVIORAL

5:2 intermittent fasting

Two nonconsecutive days of fasting per week that could be chosen freely according to the patient's weekly schedule.

Sponsors & Collaborators

  • MVZ Leopoldina GmbH

    lead OTHER

Principal Investigators

  • Rainer J Klement, Ph.D. · Department of Radiation Oncology, Leopoldina Hospital Schweinfurt

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-11-17
Completion
2022-11-17

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05861362 on ClinicalTrials.gov